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Abstract
Background: Accurate evaluation of human epidermal growth factor receptor type-2 (HER2) status based on core
needle biopsy (CNB) specimens is mandatory for identification of patients with primary breast cancer who will
benefit from primary systemic therapy with trastuzumab. The aim of the present study was to validate the
application of HER2 testing with CNB specimens from primary breast cancers in terms of interobserver
reproducibility and comparison with surgically resected specimens.
Methods: A total of 100 pairs of archival formalin-fixed paraffin-embedded CNB and surgically resected specimens
of invasive breast carcinomas were cut into sections. All 100 paired sections were subjected to HER2 testing by
immunohistochemistry (IHC) and 27 paired sections were subjected to that by fluorescence in situ hybridization
(FISH), the results being evaluated by three and two observers, respectively. Interobserver agreement levels in
terms of judgment and the concordance of consensus scores between CNB samples and the corresponding
surgically resected specimens were estimated as the percentage agreement and  statistic.
Results: In CNB specimens, the percentage interobserver agreement of HER2 scoring by IHC was 76% ( = 0.71)
for 3 × 3 categories (0-1+ versus 2+ versus 3+) and 90% ( = 0.80) for 2 × 2 categories (0-2+ versus 3+). These
levels were close to the corresponding ones for the surgically resected specimens: 80% ( = 0.77) for 3 × 3
categories and 92% ( = 0.88) for 2 × 2 categories. Concordance of consensus for HER2 scores determined by IHC
between CNB and the corresponding surgical specimens was 87% ( = 0.77) for 3 × 3 categories, and 94%
( = 0.83) for 2 × 2 categories. Among the 13 tumors showing discordance in the mean IHC scores between the
CNB and surgical specimens, the results of consensus for FISH results were concordant in 11. The rate of successful
FISH analysis and the FISH positivity rate in cases with a HER2 IHC score of 2+ differed among specimens
processed at different institutions.
Conclusion: It is mandatory to study HER2 on breast cancers, and either CNB or surgical specimen can be used.
Background
The human epidermal growth factor receptor type-2
(HER2) proto-oncogene (c-erbB-2) is amplified in 15-30%
of human breast cancers, causing overexpression of
its protein. HER2 gene amplification and/or protein
overexpression is an indicator of clinical tumor aggres-
siveness [1-3]. The efficacy of trastuzumab, a humanized
anti-HER2 monoclonal antibody, against breast cancers
with HER2 gene amplification and/or protein overexpres-
sion has been established in clinical trials for patients
with metastatic breast cancer or those with operable pri-
mary breast cancer as adjuvant systemic therapies [4-7].
Furthermore, as neoadjuvant therapy for patients with
breast cancers showing HER2 amplification and/or
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trastuzumab and chemotherapy have been shown to be
effective in achieving a complete pathological tumor
response [8,9].
HER2 testing comprises immunohistochemistry (IHC)
to examine protein overexpression and fluorescence
in situ hybridization (FISH) to examine gene amplifica-
tion. These tests are performed on tissue sections of rou-
tinely-processed formalin-fixed, paraffin-embedded
tumors. High accuracy is required for these HER2 tests
in order to identify patients who would benefit from tras-
tuzumab therapy. For the test algorithm, it is generally
recommended that IHC is performed first, and that FISH
is added if the result of IHC is equivocal [10-12]. Studies
of quality assessment have demonstrated that interobser-
ver agreement levels are high for tumors with an IHC
score of 0 or 1+, or those with a score of 3+, but that the
level is generally low for those with a score of 2+ [13-16].
A higher interobserver agreement level can be achieved
with FISH than with IHC, especially for tumors with an
IHC score of 2+ [13,14,16]. It has also been shown that
the quality of both tests is higher at institutions that per-
form a larger number of HER2 tests than at those where
a smaller number of such tests are performed [17-19].
In recent years, core needle biopsies (CNBs) have been
used for the qualitative diagnosis of breast tumors.
Because of the prevalence of primary systemic therapies
as a standard treatment for primary breast cancers, not
only hormone receptor status but also HER2 status are
generally assayed from CNB specimens to test the elig-
ibility of patients for primary systemic therapy with tras-
tuzumab [20]. However, it would be expected that
examination of CNB specimens alone might result in a
proportion of false-positive and/or false-negative results,
because CNB samples represent only part of the tumor,
notwithstanding the possible presence of intratumor
heterogeneity [21-25]. Furthermore, because of the small
volume of CNB specimens, the interobserver agreement
rate of HER2 tests for CNB specimens might be lower
than for surgically resected specimens.
Therefore, we examined the levels of interobserver
agreement for HER2 status determination in both CNB
specimens and corresponding surgically resected speci-
mens from 100 patients with primary breast cancer who
had not received primary systemic therapy. We com-
pared the HER2 protein status determined by IHC
between the CNB specimens and surgically resected spe-
cimens of the same tumor. We also compared the HER2
protein status determined by IHC, with the HER2 gene
status determined by FISH, in CNB specimens and in
the corresponding surgically resected specimens. On the
basis of these results, we evaluated the utility and chal-
lenges of HER2 testing within CNB specimens.
Methods
Tissue samples
We examined 100 paired samples of invasive breast car-
cinoma obtained by CNB and surgical resection from
patients treated at Saitama Cancer Center, Ina, Saitama
(50 cases), Tokai University Hospital, Isehara, Kanagawa
(25 cases), and the National Defense Medical College
Hospital, Tokorozawa, Saitama (25 cases), Japan. At all
three institutions, HER2 testing is performed very fre-
quently for routine diagnostics and/or for studies of
quality assessment. Collaborating pathologists in the
three institutes were assigned to submit almost equal
number of CNB cases of each score (score 0 or 1+, 2+,
and 3+), for the purpose that almost equal number of
HER2-negative, equivocal and positive cases were exam-
ined in the study. However, these institutional scores
were not informed to the pathologists on the central
review. Therefore, the cases were not consecutive and
there was some selection bias.
None of the patients with these tumors had received
neoadjuvant therapy before CNB and surgical resection.
At each institution, 4-μm-thick sections cut from routi-
nely processed formalin-fixed, paraffin-embedded tissue
blocks were subjected to immunohistochemistry and
FISH. IHC and FISH assays were performed on parallel
slides of the same CNB/surgically resected specimens.
The present study was conducted with approval from
the internal review board for ethical issues of the
National Defense Medical College. Informed consent
had been acquired from each patient for the purpose of
general research use of surgically resected tissues, and
the requirement for informed consent for the present
study was waived by the internal review board according
to the guideline of ethical issues for epidemiologic stu-
dies by the Ministry of Health, Labor and Welfare and
the Ministry of Education, Culture, Sports, Science and
Technology, Japan.
Immunohistochemistry
Expression of HER2 oncoprotein was examined using
HercepTest II (Dako, Glostrup, Denmark) in the Dako
Japan Central Laboratory, Tokyo, Japan. Deparaffiniza-
tion, antigen retrieval, and immunohistochemistry were
performed to 100 CNB and 100 paired surgically resected
tumor sections in accordance with the manufacturer’s
instructions using an Autostainer Plus (Dako) [16].
Three experienced (for >25 years) pathologists (M.K.,
S.U., H.T.), being blinded from institutional IHC results
or the present FISH results, independently evaluated the
results of IHC, and assigned a score of 0 (no staining), 1
+ (weak, incomplete membrane staining in any propor-
tion of tumor cells), 2+ (complete membrane staining
that is either nonuniform or weak in intensity but with
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tumor cells, or invasive tumors show intense, complete
membrane staining of 30% or fewer tumor cells), or 3+
(uniform, intense membrane staining of >30% of inva-
sive tumor cells) in accordance with the guidelines
of the American Society of Clinical Oncology (ASCO)/
College of American Pathologists (CAP) [10]. Scores of
0 and 1+ were categorized as IHC-negative, a score of
2+ was categorized as equivocal, and a score of 3+ was
categorized as overexpression (positive). If the score
assigned by three observers differed among the three
categories, the majority scores were acquired as consen-
sus judgments. When the judgments of the three obser-
vers differed from each other, the median value was
acquired as the representative score.
FISH
FISH was performed on all 100 CNB specimens and on
27 surgically resected specimens for which the consen-
sus judgment of the IHC result differed from that of the
CNB result and/or was discordant among the three
observers.
FISH was performed manually using a PathVysion
HER-2 DNA probe kit (Abbott Molecular, Wiesbaden,
Germany) in accordance with the manufacturer’s instruc-
tions [13] at the Department of Basic Pathology, National
Defense Medical College, Tokorozawa, Saitama, Japan.
The slides were visualized using a Leica DMR fluores-
cence microscope (Leica, Cambridge, UK). Two obser-
vers (S.Y. or T.K. and H.T.), being blinded from IHC
results and FISH results of the corresponding CNB or
surgical resection specimen, counted the signals for
HER2 and CEP17 on a total of 40 cancer cell nuclei. The
total number of HER2 signals was divided by the total
number of CEP17 signals on 40 nuclei, and the HER2/
CEP17 ratio was calculated. HER2 gene amplification was
judged as positive, equivocal, and negative if the HER2/
CEP17 ratio was more than 2.2, 1.8 to 2.2, and less than
1.8, respectively [10]. When a tumor was judged as equi-
vocal, 40 additional nuclei in another tumor area on inva-
sion were counted again by two observers. If the HER2/
CEP17 ratio was 2.0 or higher in the re-test, the tumor
was finally judged as having HER2 amplification.
Interobserver agreement
With regard to IHC and FISH, interobserver agreement
of judgments and the concordance of consensus scores
between the CNB and corresponding surgically resected
specimens were estimated in terms of percentage agree-
ment and the  statistic. The percentage of agreement
was calculated as follows:
(Number of tumors to which the three observers
assigned an identical score/total number of tumors) ×
100
The level of agreement was categorized as almost per-
fect, substantial, moderate, fair, and slight when the 
value was >0.80, >0.60-0.80, >0.40-0.60, >0.20-0.40, and
0-0.20, respectively [26,27].
Results
Interobserver agreement for IHC and FISH
For CNB specimens, the percentage interobserver agree-
ment for HER2 scores determined by IHC was 76% for
3 × 3 categories (0-1+ vs 2+ vs 3+) and 90% for 2 × 2
categories (0, 1+ or 2+ vs 3+). In terms of the  statistic,
the interobserver agreement levels were substantial for
the 3 × 3 categories ( =0 . 7 1 ,s =0 . 0 6 5 )a n dt h e2×2
categories ( =0 . 8 0 ,s = 0.075). The 24 tumors for
which judgment discordance arose for 3 × 3 categories
a r es h o w ni nT a b l e1 .A l lo ft h e s et u m o r ss h o w e dd i s -
cordance in one score, and none showed a difference in
2 scores.
Table 1 Core needle biopsy tumor specimens for which
interobserver disagreement arose regarding the results
of HER2 immunohistochemistry
Code Final
score
IHC score FISH (HER2/
CEP17)
Observer
A
Observer
B
Observer
C
B45 1+ 1+ 1+ 2+ - (0.96)
B78 1+ 1+ 1+ 2+ - (0.99)
B24 1+ 2+ 1+ 1+ - (1.01)
B82 1+ 2+ 1+ 1+ - (1.02)
B79 1+ 2+ 1+ 1+ - (1.05)
B99 1+ 1+ 1+ 2+ - (1.07)
B36 1+ 1+ 1+ 2+ - (1.11)
B22 2+ 2+ 1+ 2+ - (0.97)
B69 2+ 2+ 1+ 2+ - (1.04)
B43 2+ 2+ 1+ 2+ - (1.09)
B86 2+ 2+ 1+ 2+ - (1.39)
B29 2+ 2+ 2+ 1+ - (1.42)
B100 2+ 2+ 1+ 2+ + (2.38)
B16 2+ 3+ 2+ 2+ + (2.56)
B97 2+ 2+ 1+ 2+ + (4.56)
B52 2+ 3+ 2+ 2+ + (5.44)
B91 2+ 2+ 2+ 3+ + (6.80)
B90 2+ 3+ 2+ 2+ + (10.38)
B102 2+ 3+ 2+ 2+ + (12.62)
B50 3+ 3+ 3+ 2+ + (5.11)
B7 3+ 3+ 2+ 3+ + (8.83)
B96 3+ 3+ 2+ 3+ + (9.02)
B95 3+ 3+ 2+ 3+ + (10.92)
B27 3+ 3+ 3+ 2+ + (12.50)
The HER2 score was assigned according to the 2007 ASCO/CAP guideline [10].
The majority score was assigned as the final score for the tumor.
FISH, fluorescence in situ hybridization; IHC, immunohistochemistry
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interobserver agreement for HER2 scores determined by
IHC was 80% for the 3 × 3 categories and 92% for the
2 × 2 categories. In terms of the  statistic, the interob-
server agreement level was substantial for the 3 × 3
categories ( = 0.77, s = 0.060) and almost perfect for
the 2 × 2 categories ( =0 . 8 8 ,s = 0.051). The 20
tumors for which judgment discordance arose for 3 × 3
categories are shown in Table 2. All of these tumors
showed discordance in one score, and none showed a
difference in 2 scores.
The consensus score for HER2 expression determined
by IHC was 0 or 1+, 2+, and 3+ in 60, 19, and 21
tumors, respectively, in CNB specimens, and in 60, 15,
and 25 tumors, respectively, in surgically resected
specimens.
FISH was successful in 99 of the 100 CNB specimens.
By the first examinations, 96 tumors (97%) were judged
to have the same score by two observers. Because three
other tumors were judged differently by two observers
and the average of the two judgments was within the
range of equivocal, they were subjected to a re-count:
for two tumors, the second judgments also differed
between two observers, being positive and equivocal
respectively, but the average of the judgments of HER2/
CEP17 ratio exceeded 2.20, so they were finally judged
positive. For the other, the second judgments were com-
monly positive (Table 3). By FISH, HER2 gene amplifi-
cation was finally judged positive in 33 CNB specimens
(33%) but negative in 66 (67%).
A total of 27 surgically resected tumors were subjected
to FISH. Among the 25 surgical specimens for which
FISH was successful, only one (no. 67) was judged dif-
ferently by two observers, being positive and equivocal
respectively. However, the average of the two judgments
was within the range of positive (HER2/CEP17 ratio =
2.236), the case was judged as positive without re-eva-
luation (Table 3). In total, HER2 gene amplification in
surgically resected specimens was positive in 12 (48%)
and negative in 13 (52%).
FISH was not successful in three specimens: one CNB
and two surgically resected specimens. All three of these
specimens were processed in institution A.
Comparison of IHC and FISH test results between CNB
and surgically resected specimens
Concordance in consensus HER2 IHC scores between
CNB and the corresponding surgically resected speci-
mens was 87% for 3 × 3 categories, and 94% for 2 × 2
categories (Table 4). The  statistic indicated that their
concordance was substantial for the 3 × 3 categories
( = 0.77, s = 0.045) and almost perfect for the 2 × 2
categories ( = 0.83, s = 0.038). Representative concor-
dant cases are presented in Figure 1.
Table 2 Surgically resected tumor specimens for which
interobserver disagreement arose regarding the results
of HER2 immunohistochemistry
Code Final
score
IHC score FISH (HER2/
CEP17)
Observer
A
Observer
B
Observer
C
S54 0+ 0 2+ 0 - (0.92)
S17 1+ 1+ 1+ 2+ NA
S26 1+ 1+ 1+ 2+ - (0.68)
S78 1+ 1+ 1+ 2+ - (0.82)
S79 1+ 2+ 1+ 1+ - (0.89)
S76 1+ 2+ 1+ 1+ - (0.95)
S82 1+ 2+ 1+ 1+ - (0.97)
S77 1+ 2+ 1+ 1+ - (1.47)
S23 2+ 2+ 1+ 2+ - (0.47)
S22 2+ 2+ 1+ 2+ - (0.92)
S16 2+ 3+ 2+ 2+ - (1.03)
S84 2+ 2+ 1+ 2+ - (1.13)
S67 2+ 2+ 1+ 2+ + (2.24)
S97 2+ 3+ 2+ 2+ + (3.89)
S103 2+ 3+ 2+ 2+ + (7.75)
S91 2+ 3+ 2+ 2+ + (7.77)
S94 3+ 3+ 3+ 2+ + (3.61)
S52 3+ 3+ 3+ 2+ + (5.09)
S42 3+ 3+ 3+ 2+ + (9.24)
S18 3+ 3+ 3+ 2+ + (12.40)
The HER2 score was assigned according to the 2007 ASCO/CAP guideline [10].
The majority score was assigned as the final score for the tumor. NA, not
available because FISH was not successful.
FISH, fluorescence in situ hybridization; IHC, immunohistochemistry
Table 3 Tumor specimens for which interobserver
disagreement arose regarding the results of fluorescence
in situ hybridization
CNB specimens
Code Final
judgment
HER2/CEP17 by 1st
counts
HER2/CEP17 by 2nd
counts
Obs.
A
Obs.
B
Average Obs.
A
Obs.
B
Average
B61 Amplification 2.71 1.55 2.13 2.55 1.88 2.22
B62 Amplification 2.35 1.88 2.12 2.44 2.07 2.26
B87 Amplification 1.94 2.44 2.19 3.50 2.38 2.44
Surgically resected specimens
Code Final
judgment
HER2/CEP17 by 1st
counts
HER2/CEP17 by 2nd
counts
Obs.
A
Obs.
B
Average Obs.
A
Obs.
B
Average
S67 Amplification 2.67 1.81 2.24 ND ND -
HER2 amplification was defined as positive, equivocal, and negative when the
HER2/CEP17 ratio was more than 2.2, between 1.8 and 2.2, and less than 1.8,
respectively. For the surgically resected specimen, the average of the HER2/
CEP17 ratio (2.24) between observers (2.67 and 1.82) was adopted, because
the second count was not done (ND). Obs., observer
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CNB specimens, 56 (93%) were also judged to have a
score of 0 or 1+ but the other four were scored 2+ for
the surgically resected specimens. Among the 21 tumors
with a score of 3+ for CNB specimens, 20 (95%) were
also judged to have a score of 3+ and only one (5%) was
scored 0 for the surgically resected specimens. In con-
trast, among the 19 tumors with a score of 2+ for CNB
specimens, only 11 (58%) were also scored 2+ for the
surgically resected specimens. In three and five of these
19 cases, scores of 0 or 1+ and 3+ were assigned,
respectively, for the surgically resected specimens.
Overall, consensus HER2 IHC scores showed discor-
dance between CNB and surgically resected specimens
in 13 of 100 cases (Table 5). The discordance may have
been attributable to intratumor heterogeneity, subopti-
mal processing of the specimens, and/or the borderline
nature of the tumor. The borderline nature means that
the state of HER2 expression was borderline between 1+
and 2+ or between 2+ and 3+, namely, the conditions
that it was difficult to judge whether the entirely cir-
cumscribing membrane immunoreactivity of the HER2
was moderate (2+) or strong (3+), or whether the weak
membrane HER2 immunoreactivity was entirely (2+) or
incompletely (1+) circumscribing the membrane.
In at least five tumors (Nos. 23, 24, 54, 84, 92), the
discordance appeared to have been due to intratumor
heterogeneity. In case 54, to the surgically resected spe-
cimen, all three observers gave a score of 3+ because
>30% of cancer cells showed strong membrane staining.
In contrast, in the CNB specimen, the percentage of
cancer cells showing strong membrane staining was
around 10%, and two observers gave a score of 0, and
the other gave one of 2+ (Figure 2A). In cases 23, 24,
and 84, there appeared to be intratumor heterogeneity
ranging between areas of moderate, and no or weak,
HER2 staining (2+ vs 0 or 1+) (Figure 2B). In case 92,
the HER2 score for the predominant intraductal compo-
nent was uniformly 3+, but in the focus of invasive
carcinoma, the immunoreaction was weaker (Figure 2C).
In this case, we performed FISH on the part including
both invasive carcinoma and non-invasive components.
In 4 cases (Nos. 52, 90, 94 and 102), the HER2 score
was 2+ for the CNB specimen but 3+ for the surgical
specimen (Figure 2D). In these cases, the membrane
HER2 immunoreaction in CNB specimens was weaker
and less continuous than that in surgically resected spe-
cimens. In 5 other cases (Nos. 10, 43, 52, 67 and 69),
the intensity of the HER2 immunoreaction differed
between the CNB and surgically resected specimens, but
the immunoreaction pattern in the surgically resected
specimens was uniform. Therefore, suboptimal proces-
sing of CNB specimens or long-term fixation of surgi-
cally resected specimens might have been partly
responsible for the difference.
Interobserver disagreement regarding the HER2 score
arose for either CNB specimens or surgically resected
specimens in 11 of these 13 cases. Possible reasons for
this may have been the borderline nature of the tumors,
preanalytical factors, and/or inratumor heterogeneity
(e.g., No. 54) (Table 5).
In 23 (92%) of the 25 tumors for which HER2 FISH
was performed, consensus judgments regarding HER2
gene status were concordant between the CNB and the
surgically resected specimens, being amplified in 11 and
not amplified in 12 (Table 6). In the other two cases,
the consensus judgments were discordant between the
CNB and the surgically resected specimens: In one (no.
67), the CNB specimen showed an IHC score of 1+ with
a HER2/CEP17 ratio of 0.84, whereas the surgically
resected specimen showed an IHC score of 2+ with a
HER2/CEP17 ratio of 2.24. As mentioned above, the
case was judged differently by two observers, but the
average of the judgments made a score of positive
(Table 3). In the other, both the CNB and surgically
resected specimens showed an IHC score of 2+, and the
HER2/CEP17 ratio was 1.03 and 2.56, respectively (No.
16). For that case, there was no disagreement in HER2
score of CNB and surgically resected specimens by IHC.
Correlation between IHC and FISH results
Among the 100 CNB specimens, the percentage of
HER2 gene amplification was 95% (20 of 21), 58% (11 of
19), and 3% (2 of 60) for HER2 IHC scores of 3+, 2+,
and 0 or 1+, respectively (Table 7). With regard to
Table 4 Concordance of consensus HER2 judgments by
immunohistochemistry between core needle biopsy and
corresponding surgically resected specimens
3 categories (0 or 1+ vs. 2+ vs. 3+)
HER2 score for surgically resected specimens Number of tumors
HER2 score for CNB
specimens
0o r1 + 2 + 3 +
0o r1 + 5 6 3 1
2+ 4 11 0
3+ 0 5 20
% agreement = 87%,  = 0.77, standard deviation (s) = 0.045
2 categories (0, 1+. or 2+ vs. 3+)
HER2 score for surgically resected specimens Number of tumors
HER2 score for CNB
specimens
0, 1+ or 2+ 3+
0, 1+, or 2+ 74 1
3+ 5 20
% agreement = 94%,  = 0.83, s = 0.038
The judgments were performed according to the 2007 ASCO/CAP guideline.
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amplification differed between tumor specimens from
different institutions. In tumor specimens from institu-
tions A and B, the rates of HER2 gene amplification
were 20% (1 of 5) and 33% (1 of 3), respectively, but in
specimens from institute C, the rate was as high as 82%
(9 of 11).
For the 25 surgically resected specimens successfully
subjected to FISH, the percentage of HER2 gene amplifi-
cation was 100% (10 of 10), 43% (3 of 7), and 0% (0 of
8) for HER2 IHC scores of 3+, 2+, and 0 or 1+, respec-
tively (Table 7). In tumor specimens from institution A,
t h er a t eo fHER2 gene amplification in IHC 2+ cases
was 0% (0 of 3), whereas in specimens from institution
Figure 1 Cases with concordant judgment of HER2 score between CNB and surgically resected specimens. A-B. Case 3: HER2 score for
both the CNB specimen (A) and the surgically resected specimen (B) was 3+. C-D. Case 22: HER2 score for both the CNB specimen (C) and the
surgically resected specimen (D) was 2+. E-F. Case 2: HER2 score for both the CNB specimen (E) and the surgically resected specimen (F) was 0.
Immunoperoxidase reaction, original magnification ×200.
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Page 6 of 11C, the rate was 80% (4 of 5). No cases with a score of
2+ were subjected to FISH at institution B.
For CNB specimens, 14 cases showed interobserver dis-
agreement in HER2 IHC scores of between 1+ and 2+,
and, of these, seven tumors each were finally scored as 1
+ and 2+. Among these tumors, HER2 gene amplification
was detected in 0 (0%) and 2 (29%), respectively. The
other 10 cases showed interobserver disagreement in
HER2 IHC scores of between 2+ and 3+, and, of these,
five tumors each were finally scored as 2+ and 3+. HER2
gene amplification was detected in all of these tumors
(Table 1).
For surgically resected specimens, 12 cases showed
interobserver disagreement between IHC scores of 0/1+
and 2+, and eight and four tumors were finally scored
as 0/1+ and 2+, respectively. Among these tumors,
HER2 gene amplification was detected in 0 (0%) and 1
(25%), respectively. The other eight showed interobser-
ver discordance between IHC scores of 2+ and 3+, and
four tumors each were finally scored as 2+ and 3+.
Among these tumors, HER2 gene amplification was
detected in 3 (75%) and 4 (100%), respectively (Table 2).
In the 12 tumors showing discordance of the IHC
score for HER2 expression between the CNB and surgi-
cally resected specimens, and for which the FISH assay
was successful, judgments for the FISH results were
concordant in 11 (92%) (Table 5).
Discussion
From the viewpoint of interobserver agreement level, the
percentage agreement levels and  values among the
three observers with regard to the IHC test results were
similar between the data for CNB specimens and those
for surgically resected specimens. Furthermore, the pre-
sent study also clarified that the results of IHC for
HER2 were mostly concordant between the CNB speci-
men and the surgically resected specimen from an iden-
tical invasive breast cancer. These results indicated that
t h eC N Bs p e c i m e n sw e r eo fa d e q u a t eq u a l i t yf o rt h e
evaluation of HER2 status by IHC, and that the IHC
scores obtained for the CNB specimens were mostly
representative of the HER2 IHC scores for the entire
tumor specimen. Therefore, HER2 testing using IHC for
CNB specimens appeared to be valid for a majority of
primary breast cancers. The present results were similar
t ot h ev e r yf i r s ts t u d i e sd o n eb yC h i v u k u l ae ta l .t h a t
stated as CNB a better sample [25].
Previous reports have indicated that concordance of
HER2 IHC scores between CNB and corresponding exci-
sional biopsy/surgically resected specimens was 87-98.8%
[21-23,28]. The introduction of FISH analysis has
improved the concordance rate for HER2 status [22,25].
In the study by Apple et al., the concordance rate of 87%
for IHC was improved to 92% by FISH [22]. Intratumor
heterogeneity for HER2 amplification was reported to be
present in 13% of tumors of an IHC score of 3+, and was
especially higher in those with low-grade amplification
(ratio >2.2 to <4.0) [24]. For tumors with an IHC score of
2+, the incidence of intratumor heterogeneity in HER2
scores was also relatively frequent (14%), but FISH analy-
sis of CNB specimens almost completely resolved the
issue of heterogeneous HER2 expression [25].
Some studies had suggested that the validity of IHC
score 3+ in core biopsies was limited, reporting high
rates of false positives (19.3%). However, Moelans et al,
showed that there was only a slightly higher percentage
of IHC 3+ positivity in biopsies compared to resections,
and that did not reach statistical difference [29]. Their
results are in line with those in the present study (25%
vs 21%). In the present study, it was confirmed that con-
cordance of the HER2 test results was higher for FISH
(98%) than for IHC (87%). Among the 13 tumors that
showed discordance of HER2 IHC scores between the
CNB and surgically resected specimens, 11 showed con-
cordance of the results obtained by FISH.
The disagreement in the results obtained with IHC
between CNB and surgical specimens appeared to be
derived from 1. intratumor heterogeneity, 2. pre-analytical
factors including variations in the duration of fixation and
suboptimal tissue processing, and/or 3. borderline tumor
properties. To overcome the problem of intratumor het-
erogeneity in HER2 expression, examination of a large
volume of tumor tissue appears to be necessary. To solve
the problem of borderline tumor properties in terms of
HER2 expression, the introduction of judgment by multi-
ple observers and/or DNA copy analyses might be of
value.
Table 5 13 tumors for which interobserver disagreement
arose regarding the results of immunohistochemistry.
Code No. Immunohistochemistry FISH
– CNB Surgery Interpretation CNB Surgery
84 0 (0/0/0) 2+(2/1/2) Processing, hetero Neg Neg
23 1+(1/1/1) 2+(2/1/2) Heterogeneity Neg Neg
24 1+(2/1/1) 2+(2/2/2) Heterogeneity Neg NA
67 1+(1/0/1) 2+(2/1/2) Processing, border Neg Pos
10 2+(2/2/2) 1+(1/1/1) Processing Neg Neg
43 2+(2/1/2) 0 (0/0/0) Processing Neg Neg
69 2+(2/1/2) 1+(1/1/1) Processing, border Neg Neg
52 2+(3/2/2) 3+(3/3/2) Processing, border Pos Pos
90 2+(3/2/2) 3+(3/3/3) Processing, border Pos Pos
92 2+(2/2/2) 3+(3/3/3) Predominantly DCIS Pos Pos
94 2+(2/2/2) 3+(3/3/2) Processing, border Pos Pos
102 2+(3/2/2) 3+(3/3/3) Processing, border Pos Pos
54 3+(3/3/3) 0 (0/2/0) Heterogeneity Neg Neg
FISH, fluorescence in situ hybridization; NA, Data were not available; neg,
negative; pos, positive; parenthesis, judgments of scores by three observers
(Underlines indicate interobserver disagreement.)
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Page 7 of 11Figure 2 Cases with discordant judgment of HER2 score between CNB and surgically resected specimens. A-B. Case 54: HER2 score was
3+ for the CNB specimen (A) but 0 for the surgically resected specimen (B). The tumor had heterogeneous HER2 expression, and >30% of the
area showed a strong membrane immunoreaction in the CNB specimen, whereas most of the area in the surgically resected specimen was
HER2-negative. C-D. Case 84: HER2 score was 0 for the CNB specimen (C) but 2+ for the surgically resected specimen (D). This difference might
have been due to suboptimal processing of CNB specimens or intratumor heterogeneity. E-F. Case 92: HER2 score was 2+ for the CNB specimen
(E) but 3+ for the surgically resected specimen (F). Because the CNB specimen contained only a small amount of invasive component, the
evaluation of HER2 was difficult. G-H. Case 94: HER2 score was 2+ for the CNB specimen (G) but 3+ for the surgically resected specimen (H).
Processing of the CNB specimen might have been suboptimal, or the tumor may have been borderline in nature. Immunoperoxidase reaction,
original magnification ×200.
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Page 8 of 11From the present results, the rate of HER2 gene
amplification appeared to be low when interobserver
discordance was seen between IHC scores of 0/1+ and 2
+, whereas most tumors had gene amplification when
there was interobserver discordance between scores of 2
+ and 3+. These findings will be helpful for the decision
if subsequent FISH should be performed or not. For 2
+/3+ discrepancies FISH test should always be added
because the percentage of HER2 amplification is high.
Counting of HER2 gene copies by FISH, chromogenic in
situ hybridization (CISH), silver-enhanced in situ hybri-
dization (SISH), or dual-color dual-hapten in situ hybri-
dization (DDISH) would greatly improve the
concordance of HER2 status between CNB and surgi-
cally resected specimens [30-32].
Another important factor to be considered is the prea-
nalytical condition of the specimens. In the present
study, FISH analysis was sometimes unsuccessful for
specimens processed at institution A, whereas FISH was
always successful for specimens processed at institutions
B and C. Interview revealed that the suboptimal FISH
results obtained at institution A were attributable to
l o n g - t e r m( a b o u t1w e e k )f i x a t i o no ft h es p e c i m e n s .I t
was shown that a prolonged formalin fixation could lose
FISH amplification and/or yield to unsuccessful test
(Hiroi S, Tsuda H et al, manuscript in preparation) [33].
On the other hand, the localization of the HER2 immu-
noreaction on the cancer cell membrane was not uniform
in CNB specimens from HER2-positive tumors processed
at institution C, whereas this was not an evident feature
in specimens processed at other institutions or in surgi-
cally resected specimens. The reason for this unusual
immunoreaction is unclear. It has been shown that qual-
ity assessment of HER2 tests is very important for identi-
fying patients who are very likely to benefit from therapy
with trastuzumab [10,34,35]. For quality assessment, not
only improvement of the interobserver agreement level
but also standardization of pre-analytical specimen pre-
paration should be taken into consideration.
Conclusion
We have clarified that CNB specimens showed almost
equal reliability to surgically resected specimens for test-
ing of HER2 expression in terms of interobserver agree-
ment levels and concordance with FISH results. In most
of specimens with equivocal IHC results, accurate HER2
status was known determined by retesting with FISH.
To further improve the reliability of HER2 tests using
CNB specimens, it might be useful to sample a larger
volume of tumor tissue, to conduct evaluation by multi-
ple observers, and to take measures to improve the pre-
analytical conditions of the specimens.
List of abbreviations used
CNB: core needle biopsy; FISH: fluorescence in situ hybridization; HER2:
human epidermal growth factor receptor type-2; IHC: immunohistochemistry
Table 6 Concordance of consensus HER2 FISH results of between core needle biopsy and surgically resected
specimens
HER2/CEP17 ratio for surgically resected specimens Number of tumors
HER2/CEP17 ratio for CNB specimens
> 2.2 1.8 to 2.2 <1.8
Higher than 2.2 11 0 1
1.8 to 2.2 00 0
<1.8 10 1 2
% agreement = 92%
The judgments were performed according to the 2007 ASCO/CAP guideline. For two tumors, data on CNB and/or surgically resected specimens were not
available.
Table 7 Correlation between consensus
immunohistochemistry and FISH results for core needle
biopsy and surgically resected specimens
Core needle biopsy specimens
Number of tumors (%)
Total HER2 gene amplification by FISH
Positive Equivocal* Negative
HER2 IHC score
3+ 21 20 (95) 0 (0) 1 (5)
2+ 19 11 (58) 0 (0) 8 (42)
0 or 1+ 60 2 (3) 0 (0) 58 (97)
Total 100 33 (33) 0 (0) 67 (67)
Surgically resected specimens
Number of tumors (%)
Total HER2 gene amplification by FISH
Positive Equivocal* Negative
HER2 IHC score
3+ 10 10(100) 0 (0) 0 (0)
2+ 7 3 (43) 0 (0) 4 (57)
0 or 1+ 8 0 (0) 0 (0) 8 (100)
Total 25 13 (52) 0 (0) 12 (48)
*For three tumors, FISH judgment was equivocal by the first counts, but by
the second counts, the judgments changed into positive (Table 3). FISH,
fluorescence in situ hybridization
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